Description

Simple

A medication used to treat skin infections caused by specific types of bacteria.

Clinical

An antibacterial used to treat acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible strains of Gram-positive bacteria.

Overview

Dalbavancin is a second-generation lipoglycopeptide antibiotic that was designed to improve on the natural glycopeptides currently available, such as vancomycin and teicoplanin [1, 2]. Modifications from these older glycoprotein classes facilitated a similar mechanism of action for dalbavancin but with increased activity and once-weekly dosing [FDA Label, 4, 1, 2]. Its use is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by the following gram-positive microorganisms: Staphylococcus... Read more

Pharmacology

Indication

Dalbavancin for injection is indicated for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI), caused by susceptible isolates of the following gram-positive microorganisms: Staphylococcus aureus (including methicillin-susceptible and methicillin-resistan... Read more

Pharmacodynamic

The antibacterial activity of dalbavancin appears to best correlate with the ratio of area under the concentration-time curve to minimal inhibitory concentration (AUC/MIC) for Staphylococcus aureus based on animal models of infection [FDA Label, Read more

Mechanism of action

Dalbavancin has a spectrum and mechanism of action similar to vancomycin, a naturally formed glycopeptide antimicrobial [ Read more

Absorption

In healthy subjects, dalbavancin AUC0-24h and Cmax both increased proportionally to dose following single intravenous (IV) dalbavancin doses ranging from 140 mg to 1500 mg, indicating linear pharmacokinetics [FDA Label, Read more

Protein binding

Dalbavancin is reversibly bound to human plasma proteins, primarily to albumin [FDA Label, 4]. The plasma protein binding of dalbavancin is 93% and is not altered as a function of drug concentrati... Read more

Volume of distribution

Clearance and volume of distribution at steady state are comparable between healthy subjects and patients with infections [5]. The volume of distribution at steady state was similar to the volume of extracellular flui... Read more

Clearance

0.0513 L/h [FDA Label, 4].

Half life

Terminal half life is 346 hours [FDA Label, 4].

Route of elimination

Following administration of a single 1000 mg dose in healthy subjects, an average of 33% of the administered dalbavancin dose was excreted in urine as unchanged dalbavancin and approximately 12% of the administered dose was excreted in urine as the metabolite hydroxy-dalbavancin through 42 days post... Read more

Toxicity

Treatment with antibacterial agents can alter the normal flora of the colon leading to growth of C. difficile and commonly occurs in the development of C. difficile-associated diarrhea [FDA Label, 4 Read more

Adverse Effects

Contraindications

Information currently not available.

Food Interactions

    Information currently not available.

Interactions

Type in a drug name to check for interaction with Dalbavancin
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
(R)-warfarin
The risk or severity of bleeding can be increased when Dalbavancin is combined with (R)-warfarin.
(S)-Warfarin
The risk or severity of bleeding can be increased when Dalbavancin is combined with (S)-Warfarin.
4-hydroxycoumarin
The risk or severity of bleeding can be increased when Dalbavancin is combined with 4-hydroxycoumarin.
Acenocoumarol
The risk or severity of bleeding can be increased when Dalbavancin is combined with Acenocoumarol.
BCG vaccine
The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Dalbavancin.
Clorindione
The risk or severity of bleeding can be increased when Dalbavancin is combined with Clorindione.
Coumarin
The risk or severity of bleeding can be increased when Dalbavancin is combined with Coumarin.
Dicoumarol
The risk or severity of bleeding can be increased when Dalbavancin is combined with Dicoumarol.
Diphenadione
The risk or severity of bleeding can be increased when Dalbavancin is combined with Diphenadione.
Ethyl biscoumacetate
The risk or severity of bleeding can be increased when Dalbavancin is combined with Ethyl biscoumacetate.
Fluindione
The risk or severity of bleeding can be increased when Dalbavancin is combined with Fluindione.
Phenindione
The risk or severity of bleeding can be increased when Dalbavancin is combined with Phenindione.
Phenprocoumon
The risk or severity of bleeding can be increased when Dalbavancin is combined with Phenprocoumon.
Tioclomarol
The risk or severity of bleeding can be increased when Dalbavancin is combined with Tioclomarol.
Typhoid vaccine
The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Dalbavancin.
Warfarin
The risk or severity of bleeding can be increased when Dalbavancin is combined with Warfarin.
5 References
  1. 1 . Bailey J, Summers KM: Dalbavancin: a new lipoglycopeptide antibiotic. Am J Health Syst Pharm. 2008 Apr 1;65(7):599-610. doi: 10.2146/ajhp070255.PubMed: 18359966
  2. 2 . Bennett JW, Lewis JS, Ellis MW: Dalbavancin in the treatment of complicated skin and soft-tissue infections: a review. Ther Clin Risk Manag. 2008 Feb;4(1):31-40.PubMed: 18728718
  3. 3 . Leuthner KD, Yuen A, Mao Y, Rahbar A: Dalbavancin (BI-387) for the treatment of complicated skin and skin structure infection. Expert Rev Anti Infect Ther. 2015 Feb;13(2):149-59. doi: 10.1586/14787210.2015.995633.PubMed: 25578881
  4. 4 . Dalbavacin Health Canada Product Monograph File
  5. 5 . Dalbavancin EMA Label File